{"id":65138,"date":"2026-07-21T10:00:00","date_gmt":"2026-07-21T03:00:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=65138"},"modified":"2026-07-21T10:00:00","modified_gmt":"2026-07-21T03:00:00","slug":"menarini-asia-pacific-and-pharmacosmos-partner-to-bring-first-in-class-oncology-supportive-care-therapy-cosela-to-asian-patients","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=65138","title":{"rendered":"Menarini Asia-Pacific and Pharmacosmos partner to bring first-in-class oncology supportive care therapy Cosela\u00ae to Asian patients"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

SINGAPORE<\/span>, July 21, 2026<\/span> \/PRNewswire\/ —\u00a0Menarini Asia-Pacific today announced an exclusive partnership with Pharmacosmos A\/S to register, commercialise and distribute Cosela\u00ae<\/sup> (trilaciclib) across its Asia-Pacific markets.<\/p>\n

\n<\/div>\n

Chemotherapy-induced myelosuppression (CIM) is a potentially debilitating side effect that damages bone marrow, significantly impacting its hematopoietic function (or its ability to produce healthy blood cells).\u00a0 For patients with extensive-stage small cell lung cancer (ES-SCLC), chemotherapy remains a cornerstone of treatment, yet it is a major dose limiting complication that can disrupt treatment and compromise outcomes[1]<\/span><\/sup>. Cosela\u00ae<\/sup> is a first-in-class prophylactic therapy[2]<\/span><\/sup> FDA approved to help protect bone marrow from CIM, addressing a significant unmet need in oncology supportive care for these patients.<\/p>\n

Under the agreement, Menarini Asia-Pacific will manage all aspects of registration, reimbursement, commercialisation and distribution of Cosela\u00ae<\/sup> in Australia, Hong Kong\/Macau, Indonesia, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam.<\/p>\n

“Cosela\u00ae<\/sup> represents an important advancement in oncology supportive care and the kind of innovation that can make a meaningful difference for patients,” said Glen Godresse, Chief Executive Officer of Menarini Asia-Pacific<\/b>. “Partnerships like this are central to Menarini Asia-Pacific’s mission of helping innovative therapies reach patients with our end-to-end capabilities. We look forward to working with Pharmacosmos to expand access to Cosela\u00ae<\/sup> across our region and help more patients benefit from this first-in-class treatment.”<\/p>\n

“As we looked to expand access to Cosela\u00ae<\/sup> across Asia-Pacific, we wanted a long-term partner with the capabilities to support every stage of the journey, from registration through to commercialization and patient access,” said Klaus Abel, Vice President, Global Commercial Partnerships, Pharmacosmos<\/b>. “Menarini Asia-Pacific’s deep local market expertise and patient-focused approach make them the ideal partner to bring this important innovation to patients across the region.”<\/p>\n

Cosela\u00ae<\/sup> is currently marketed in the United States and China and is under registration in Europe. Subject to regulatory approvals, the first Asia-Pacific launch is anticipated in Hong Kong in 2028, followed by other markets thereafter.<\/p>\n

The partnership builds on an existing relationship between the two companies, following a 2024 agreement to commercialise innovative iron infusion Monofer\u00ae<\/sup> across key Asia-Pacific markets.<\/p>\n

\n\n\n\n\n\n
\n

References<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

[1]. Weiss JM et al.\u00a0Managing Chemotherapy-Induced Myelosuppression with Trilaciclib. <\/i>Clin Lung Cancer. 2021. Available at: https:\/\/pubmed.ncbi.nlm.nih.gov\/33895103\/<\/a><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

[2]. Alqahtani S, Alzahrani A, Alhakamy NA, et al.\u00a0Trilaciclib: a first-in-class CDK4\/6 inhibitor with dual roles in myelopreservation and cell cycle regulation.<\/i> Medicinal Chemistry Research. 2024. Available at: https:\/\/link.springer.com\/article\/10.1007\/s00044-024-03288-y<\/a>\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n

This press release is intended for media and investor relations purposes only and does not constitute medical advice, product promotion or a recommendation for the use of any medicinal product. Cosela\u00ae<\/sup> (trilaciclib) is subject to local regulatory approvals.<\/i><\/p>\n

About Menarini Asia-Pacific
<\/b>Menarini Asia-Pacific is a member of the Menarini Group, a leading international pharmaceutical and diagnostic company with a heritage of over 135 years and over 17,000 employees in 140 countries. Here in Asia-Pacific, Menarini’s vision is to be a leading provider of important healthcare brands to improve the lives of people. Menarini Asia-Pacific operates across the entire commercial value chain, from clinical development, regulatory approval, and product launch to lifecycle management with a diverse portfolio of proprietary and partnered brands in key therapeutic fields, including Consumer Health, Dermatology, Allergy\/Respiratory, Gastroenterology, Cardio-metabolic, Oncology\/Specialty Care and Men’s Health.\u00a0<\/p>\n

\n<\/div>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

SINGAPORE<\/span>, July 21, 2026<\/span> \/PRNewswire\/ —\u00a0Menarini Asia-Pacific today announced an exclusive partnership with Pharmacosmos A\/S to register, commercialise and distribute Cosela\u00ae<\/sup> (trilaciclib) across its Asia-Pacific markets.<\/p>\n

\n<\/div>\n

Chemotherapy-induced myelosuppression (CIM) is a potentially debilitating side effect that damages bone marrow, significantly impacting its hematopoietic function (or its ability to produce healthy blood cells).\u00a0 For patients with extensive-stage small cell lung cancer (ES-SCLC), chemotherapy remains a cornerstone of treatment, yet it is a major dose limiting complication that can disrupt treatment and compromise outcomes[1]<\/span><\/sup>. Cosela\u00ae<\/sup> is a first-in-class prophylactic therapy[2]<\/span><\/sup> FDA approved to help protect bone marrow from CIM, addressing a significant unmet need in oncology supportive care for these patients.<\/p>\n

Under the agreement, Menarini Asia-Pacific will manage all aspects of registration, reimbursement, commercialisation and distribution of Cosela\u00ae<\/sup> in Australia, Hong Kong\/Macau, Indonesia, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam.<\/p>\n

“Cosela\u00ae<\/sup> represents an important advancement in oncology supportive care and the kind of innovation that can make a meaningful difference for patients,” said Glen Godresse, Chief Executive Officer of Menarini Asia-Pacific<\/b>. “Partnerships like this are central to Menarini Asia-Pacific’s mission of helping innovative therapies reach patients with our end-to-end capabilities. We look forward to working with Pharmacosmos to expand access to Cosela\u00ae<\/sup> across our region and help more patients benefit from this first-in-class treatment.”<\/p>\n

“As we looked to expand access to Cosela\u00ae<\/sup> across Asia-Pacific, we wanted a long-term partner with the capabilities to support every stage of the journey, from registration through to commercialization and patient access,” said Klaus Abel, Vice President, Global Commercial Partnerships, Pharmacosmos<\/b>. “Menarini Asia-Pacific’s deep local market expertise and patient-focused approach make them the ideal partner to bring this important innovation to patients across the region.”<\/p>\n

Cosela\u00ae<\/sup> is currently marketed in the United States and China and is under registration in Europe. Subject to regulatory approvals, the first Asia-Pacific launch is anticipated in Hong Kong in 2028, followed by other markets thereafter.<\/p>\n

The partnership builds on an existing relationship between the two companies, following a 2024 agreement to commercialise innovative iron infusion Monofer\u00ae<\/sup> across key Asia-Pacific markets.<\/p>\n

\n\n\n\n\n\n
\n

References<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

[1]. Weiss JM et al.\u00a0Managing Chemotherapy-Induced Myelosuppression with Trilaciclib. <\/i>Clin Lung Cancer. 2021. Available at: https:\/\/pubmed.ncbi.nlm.nih.gov\/33895103\/<\/a><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

[2]. Alqahtani S, Alzahrani A, Alhakamy NA, et al.\u00a0Trilaciclib: a first-in-class CDK4\/6 inhibitor with dual roles in myelopreservation and cell cycle regulation.<\/i> Medicinal Chemistry Research. 2024. Available at: https:\/\/link.springer.com\/article\/10.1007\/s00044-024-03288-y<\/a>\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

This press release is intended for media and investor relations purposes only and does not constitute medical advice, product promotion or a recommendation for the use of any medicinal product. Cosela\u00ae<\/sup> (trilaciclib) is subject to local regulatory approvals.<\/i><\/p>\n

About Menarini Asia-Pacific
<\/b>Menarini Asia-Pacific is a member of the Menarini Group, a leading international pharmaceutical and diagnostic company with a heritage of over 135 years and over 17,000 employees in 140 countries. Here in Asia-Pacific, Menarini’s vision is to be a leading provider of important healthcare brands to improve the lives of people. Menarini Asia-Pacific operates across the entire commercial value chain, from clinical development, regulatory approval, and product launch to lifecycle management with a diverse portfolio of proprietary and partnered brands in key therapeutic fields, including Consumer Health, Dermatology, Allergy\/Respiratory, Gastroenterology, Cardio-metabolic, Oncology\/Specialty Care and Men’s Health.\u00a0<\/p>\n

\n<\/div>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-65138","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/65138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65138"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/65138\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65138"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65138"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}